



CORRECTION

Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM

Ichiro Nakamura · Hiroshi Maegawa · Kazuyuki Tobe · Satoshi Uno

Published online: May 20, 2021
© The Author(s) 2021

Correction to: Diabetes Ther (2021) 12:1359–1378
<https://doi.org/10.1007/s13300-021-01042-w>

In the original article, Table 2 was published with an error. The correct Table 2 is given below.

Original

Table 2 Adverse drug reactions in the safety analysis population (first age category analysis) of STELLA-LONG TERM, in pre-approval clinical trials, and STELLA-ELDER

The original article can be found online at <https://doi.org/10.1007/s13300-021-01042-w>.

I. Nakamura (✉)
Operational Excellence, Medical Affairs Japan,
Astellas Pharma Inc., Tokyo, Japan
e-mail: ichiro.nakamura@astellas.com

H. Maegawa
Department of Medicine, Shiga University of
Medical Science, Shiga, Japan

K. Tobe
First Department of Internal Medicine, Graduate
School of Medicine and Pharmaceutical Sciences for
Research, University of Toyama, Toyama, Japan

S. Uno
Data Science, Development, Astellas Pharma Inc.,
Tokyo, Japan

ADRs, <i>n</i> (%)	Pre-approval (<i>n</i> = 1669) [2–7]	STELLA-LONG TERM			<i>P</i> -value ^a	STELLA-ELDER (<i>n</i> = 8505) [9]
		All (<i>n</i> = 11,051)	< 65 years (<i>n</i> = 7894)	≥ 65 years (<i>n</i> = 3157)		
Any ADR	549 (32.89)	2129 (19.27)	1528 (19.36)	601 (19.04)	0.701	1438 (16.9)
Serious ADR	14 (0.8)	210 (1.90)	122 (1.55)	88 (2.79)	< 0.001	127 (1.5)
ADRs of special interest						
Polyuria/ pollakiuria	168 (10.0)	612 (5.54)	471 (5.97)	141 (4.47)	0.002	170 (2.0)
Volume depletion	73 (4.5)	243 (2.20)	167 (2.12)	76 (2.41)	0.345	266 (3.1)
Skin complications	59 (4.0)	198 (1.79)	128 (1.62)	70 (2.22)	0.033	269 (3.2)
Renal disorder	76 (4.8)	191 (1.73)	119 (1.51)	72 (2.28)	0.005	118 (1.4)
Urinary tract infection	29 (1.8)	170 (1.54)	115 (1.46)	55 (1.74)	0.271	118 (1.4)
Genital infection	32 (2.0)	161 (1.46)	126 (1.60)	35 (1.11)	0.053	166 (2.0)
Hepatic disorder	17 (1.0)	133 (1.20)	110 (1.39)	23 (0.73)	0.004	19 (0.2)
Cardiovascular disease	16 (1.0)	67 (0.61)	50 (0.63)	17 (0.54)	0.562	24 (0.3)
Hypoglycemia	22 (1.4)	57 (0.52)	34 (0.43)	23 (0.73)	0.048	58 (0.7)
Malignant tumor	4 (0.2)	51 (0.46)	19 (0.24)	32 (1.01)	< 0.001	11 (0.1)
Cerebrovascular disease	4 (0.2)	48 (0.43)	29 (0.37)	19 (0.60)	0.090	36 (0.4)
Ketone body related events	11 (1.0)	7 (0.06)	6 (0.08)	1 (0.03)	– ^b	2 (0.02)
Fracture	0	4 (0.04)	4 (0.05)	0	– ^b	2 (0.02)
Lower limb amputation	0	0	0	0	– ^b	0

No. of patients (%) are shown

ADR adverse drug reaction

^a Chi-squared test for difference between BMI subgroups

^b No *P* value was calculated when at least one element of the contingency table was < 10

Correct Table 2

Table 2 Adverse drug reactions in the safety analysis population (first age category analysis) of STELLA-LONG TERM, in pre-approval clinical trials, and STELLA-ELDER

ADRs, <i>n</i> (%)	Pre-approval (<i>n</i> = 1669) [2–7]	STELLA-LONG TERM			<i>P</i> -value ^a	STELLA-ELDER (<i>n</i> = 8505) [9]
		All (<i>n</i> = 11,051)	< 65 years (<i>n</i> = 7894)	≥ 65 years (<i>n</i> = 3157)		
Any ADR	549 (32.89)	2129 (19.27)	1528 (19.36)	601 (19.04)	0.701	1438 (16.9)
Serious ADR	14 (0.8)	210 (1.90)	122 (1.55)	88 (2.79)	< 0.001	127 (1.5)
ADRs of special interest						
Polyuria/ pollakiuria	163 (10.0)	612 (5.54)	471 (5.97)	141 (4.47)	0.002	170 (2.0)
Volume depletion	73 (4.5)	243 (2.20)	167 (2.12)	76 (2.41)	0.345	266 (3.1)
Skin complications	59 (3.5)	198 (1.79)	128 (1.62)	70 (2.22)	0.033	269 (3.2)
Renal disorder	76 (4.6)	191 (1.73)	119 (1.51)	72 (2.28)	0.005	118 (1.4)
Urinary tract infection	29 (1.8)	170 (1.54)	115 (1.46)	55 (1.74)	0.271	118 (1.4)
Genital infection	32 (2.0)	161 (1.46)	126 (1.60)	35 (1.11)	0.053	166 (2.0)
Hepatic disorder	17 (1.0)	133 (1.20)	110 (1.39)	23 (0.73)	0.004	19 (0.2)
Cardiovascular disease	16 (1.0)	67 (0.61)	50 (0.63)	17 (0.54)	0.562	24 (0.3)
Hypoglycemia	22 (1.4)	57 (0.52)	34 (0.43)	23 (0.73)	0.048	58 (0.7)
Malignant tumor	4 (0.2)	51 (0.46)	19 (0.24)	32 (1.01)	< 0.001	11 (0.1)
Cerebrovascular disease	4 (0.2)	48 (0.43)	29 (0.37)	19 (0.60)	0.090	36 (0.4)
Ketone body related events	11 (0.7)	7 (0.06)	6 (0.08)	1 (0.03)	– ^b	2 (0.02)
Fracture	0	4 (0.04)	4 (0.05)	0	– ^b	2 (0.02)
Lower limb amputation	0	0	0	0	– ^b	0

No. of patients (%) are shown

ADR adverse drug reaction

^a Chi-squared test for difference between BMI subgroups^b No *P* value was calculated when at least one element of the contingency table was < 10

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.